Development and Internal Validation of a Predictive Model for Prognostic Response to Proton Pump Inhibitors in Adults with Functional Dyspepsia

Authors

DOI:

https://doi.org/10.52787/agl.v54i3.422

Keywords:

Functional dyspepsia, proton pump inhibitors

Abstract

Introduction. The response to proton pump inhibitor treatment in functional dyspepsia varies among patients. A decision tool that identifies the probability of response based on clinical data could optimize management in these patients. 

Objective. To develop and internally validate an easy-to-use predictive model that enables clinicians to establish the probability of response to proton pump inhibitors in patients with functional dyspepsia. 

Material and methods. We conducted a cross-sectional study on adults with functional dyspepsia. A pilot study identified variables related to response to proton pump inhibitors. Internal validation was performed by split-sample method, with 70% for model development and 30% for validation. We developed the model using multivariable logistic regression, and selected variables based on the best subset method. The final model was subsequently transformed into a scoring rule. Predictive ability was assessed using the area under the curve (AUC) and Hosmer-Lemeshow statistic. 

Results. A total of 192 patients were included. The best subset identified 4 variables with the best performance. The logistic model showed good calibration and discrimination with an AUC of 0.89 and a Hosmer-Lemeshow chi-square test with p = 1. The scoring rule assigned the following values: anxiety symptoms (3 points), fibromyalgia (2 points), depression (1 point), and female sex (− 1 point). A total score of 4 points or less was associated with a good response to proton pump inhibitor treatment, with a sensitivity of 96.5% and specificity of 56.6%. 

Conclusions. We present a novel tool that facilitates the early identification of patients with a better therapeutic response to the management of functional dyspepsia.

References

-1. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet. 2020;396(10263):1689-702.

-2. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-92.

-3. Aro P, Talley NJ, Agréus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, et al. Functional dyspepsia impairs quality of life in the adult population: Functional dyspepsia and quality of life. Aliment Pharmacol Ther. 2011;33(11):1215-24.

-4. Harer KN, Hasler WL. Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options. Gastroenterol Hepatol. 2020;16(2):66-74.

-5. Wauters L, Talley NJ, Walker MM, Tack J, Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020;69(3):591-600.

-6. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Upper GI and Pancreatic Diseases Group, editor. Cochrane Database Syst Rev [Internet]. 21 de noviembre de 2017 [citado 27 de enero de 2019]; Disponible en: http://doi.wiley.com/10.1002/14651858.CD011194.pub3

-7. Nagahara A, Miwa H, Asaoka D, Shimada Y, Sasaki H, Matsumoto K, et al. Pretreatment prediction of symptom response to proton pump inhibitor therapy. J Gastroenterol Hepatol. 2015;30 Suppl 1:25-30.

-8. Hsu YC, Liou JM, Yang TH, Hsu WL, Lin HJ, Wu HT, et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol. 2011;46(2):183-90.

-9. Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H. Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther. 2003;18(1):117-24.

-10. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Ann Intern Med. 2015;162(1):55-63.

-11. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113-22.

-12. Sullivan LM, Massaro JM, D’Agostino RB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med. 2004;23(10):1631-60.

-13. Kugler TE. [ANXIETY AND DEPRESSIVE DISORDERS IN FUNCTIONAL DYSPEPSIA: CAUSE OR CONSEQUENCE?]. Eksp Klin Gastroenterol Exp Clin Gastroenterol. 2015;(9):29-35.

Published

2024-09-30

How to Cite

Niño Ramírez, S. F., Osorio, L., Santisteban, M., Roldán, L. F., León, S., & Guevara, L. G. (2024). Development and Internal Validation of a Predictive Model for Prognostic Response to Proton Pump Inhibitors in Adults with Functional Dyspepsia. Acta Gastroenterológica Latinoamericana, 54(3), 247–253. https://doi.org/10.52787/agl.v54i3.422

Similar Articles

You may also start an advanced similarity search for this article.